| calcipotriol/betamethasone dipropionate / Generic mfg. |
NCT01607853: A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris |
|
|
| Completed | 2a | 24 | Europe | Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes), Daivobet® gel applied for 24 hours (+/- 2 hours), Daivobet® gel vehicle applied for 24 hours (+/- 2 hours) | LEO Pharma | Psoriasis Vulgaris | 10/12 | 10/12 | | |
| Completed | 2a | 50 | Europe | LP0113 aerosol spray, Aerosol spray vehicle, LEO 90100 aerosol foam, Betamethasone dipropionate aerosol spray, Calcipotriol aerosol spray, Daivobet® gel | LEO Pharma | Skin and Connective Tissue Diseases | 06/15 | 06/15 | | |
| Completed | 2 | 360 | Canada, Europe | Calcipotriol plus betamethasone dipropionate (LEO 80185) gel | LEO Pharma | Psoriasis Vulgaris | | 05/06 | | |
| Completed | 2 | 24 | Europe | Daivobet® ointment, Betnovat® ointment, Diprosalic ointment, Dermovat ointment, Elocon ointment, Daivobet® ointment vehicle | LEO Pharma | Psoriasis Vulgaris | 03/09 | 05/09 | | |
NCT00875277: A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products |
|
|
| Completed | 2 | 24 | Europe | LEO 29102 cream, LEO 29102 Cream Vehicle, Betamethasone Dipropionate Cream, LEO 29102 Plus Calcipotriol Cream, LEO 29102 Plus Betamethasone Dipropionate, Daivobet® Ointment | LEO Pharma | Psoriasis Vulgaris | 05/09 | 07/09 | | |
NCT01347255: A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris |
|
|
| Completed | 2 | 24 | Europe | LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, LEO 90100 cutaneous spray, ointment, vehicle, Daivobet® ointment, Taclonex® ointment | LEO Pharma | Psoriasis Vulgaris | 06/11 | 06/11 | | |
NCT01229098: Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris |
|
|
| Completed | 2 | 102 | Canada | LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension) | LEO Pharma | Psoriasis Vulgaris | 09/11 | 10/11 | | |
|
NCT00817219: Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris |
|
|
| Completed | 2 | 33 | US | Calcipotriene plus betamethasone dipropionate ointment | LEO Pharma | Psoriasis Vulgaris | 12/11 | 12/11 | | |
NCT01083758: Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis |
|
|
| Completed | 2 | 31 | US | LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel), LEO 80185 topical suspension | LEO Pharma | Scalp Psoriasis | 08/12 | 10/12 | | |
|
|
| Completed | 2 | 78 | Canada, Europe | LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension) | LEO Pharma | Scalp Psoriasis | 08/12 | 10/12 | | |
|
NCT01536938: LEO 90100 in the Treatment of Psoriasis Vulgaris |
|
|
| Completed | 2 | 303 | US | LEO 90100, calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), Calcipotriol, Betamethasone | LEO Pharma | Psoriasis Vulgaris | 09/12 | 11/12 | | |
NCT01536886: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris |
|
|
| Completed | 2 | 376 | US | LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle | LEO Pharma | Psoriasis Vulgaris | 09/12 | 11/12 | | |
| Completed | 2 | 40 | Europe | MC2-01 (calcipotriol + BDP), MC2-01 (BDP), MC2-01 (calcipotriol), Ointment, Gel, Daivobet Ointment, Daivobet Gel | Drug Delivery Solutions ApS, Drug Delivery Solutions ApS | Patients with stable plaque type psoriasis (sufficient number and size of psoriatic plaques(s), Patients with plaque psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2006-001186-42: Determination of antipsoriatic efficacy of topical formulations in a psoriasis plaque test |
|
|
| Completed | 2 | 15 | Europe | ASF-1075, Daivobet Salbe, Daivobet Salbe, Daivonex, Daivobet Salbe, Daivonex | Astion Danmark A/S | male or female subjects with chronic plaque type psoriasis | | 08/06 | | |
2006-007069-35: Evaluation of Neodymium YAG laser-treatment compared to topical treatment with betamethasondipropionaat/calcipotriol ointment (Dovobet) for patients with chronic plaque type psoriasis |
|
|
| Ongoing | 2 | 10 | Europe | Dovobet, Dovobet, Dovobet | University Medical Centre St Radboud, Department of Dermatology | Chronic localized Psoriasis vulgaris | | | | |
2006-006487-32: CLINICAL EFFICACY EVALUATION OF A FIXED COMBINATION OF CALCITRIOL 3 µg/g WITH THREE CONCENTRATIONS (100, 250, 500µg/g) OF CLOBETASOL PROPIONATE AS SPRAY FORMULATION USING THE MODIFIED DUMAS-SCHOLTZ PSORIASIS MINI PLAQUE TEST UNDER NON-OCCLUSIVE CONDITIONS |
|
|
| Ongoing | 2 | 32 | Europe | Calcitriol 0.0003%/Clobetasol 0.01% ethanolic spray, Calcitriol 0.0003%/Clobetasol 0.025% ethanolic spray, Calcitriol 0.0003%/Clobetasol 0.05% ethanolic spray, Calcitriol 0%/Clobetasol 0.01% ethanolic spray, Calcitriol 0%/Clobetasol 0.025% ethanolic spray, Calcitriol 0%/Clobetasol 0.05% ethanolic spray, DERMOVAL CREAM, DAIVOBET OINTMENT, CD2027/CD0154, CD0154, D05AX52, Dermoval® cream, Daivobet Ointment, Dermoval® cream, Daivobet Ointment | GALDERMA R&D SNC | Treatment of psoriasis vulgaris | | | | |
2007-005463-10: A plaque test comparing three marketed products and two products in development and a vehicle control for the treatment of psoriasis vulgaris |
|
|
| Ongoing | 2 | 24 | Europe | Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g, Calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g, LEO 80185 gel, LEO 80190 ointment, Daivobet® ointment, Daivonex® cream, Daivonex® ointment, Daivobet® ointment, Daivonex® cream, Daivonex® ointment | LEO Pharma A/S | Psoriasis vulgaris lesions located on the arms, legs or trunk. | | | | |
2008-005518-29: An exploratory, open-label, intra-individual,active- controlled study comparing the efficacy and safety of Betesil versus Daivobet for the treatment of chronic plaque psoriasis |
|
|
| Ongoing | 2 | 20 | Europe | BETESIL, DAIVOBET, BETESIL, Daivobet, BETESIL, Daivobet | Laboratoires GENEVRIER | Chronic plaque psoriasis | | | | |
2014-001440-38: Methods to increase formation of a photosentisizer in the skin of healthy volunteers |
|
|
| Completed | 2 | 30 | Europe | Metvix, Daivobet, Diprosalic, Ameluz, Metvix, Daivobet, Diprosalic, Ameluz | Department of Dermatology D92, Bispebjerg Hospital, Department of Dermatology D92, Bispebjerg Hospital | Healthy volunteers - no medical condition is investigated but pharmaco kinetics | | 09/14 | | |
2015-003893-34: STUDY OF THE EFFICACY AND SAFETY OF A PAD™ CALCIPOTRIOL CREAM IN THE PSORIASIS PLAQUE TEST ETUDE DE L’EFFICACITE ET DE LA TOLERANCE DU PAD™ CALCIPOTRIOL CREME DANS LE TEST DE LA PLAQUE PSORIASIQUE |
|
|
| Not yet recruiting | 2 | 24 | Europe | PAD™ calcipotriol cream, PAD™ combination cream, DAIVOBET, DAIVONEX, CALCIPOTRIOL SANDOZ, MC2-01 (calcipotriol), MC2-01 (calcipotriol/betamethasone dipropionate), Cream, Ointment, DAIVOBET, DAIVONEX, CALCIPOTRIOL SANDOZ | Drug Delivery Solutions Aps (DDS) c/o MC2 Biotek Group, Drug Delivery Solutions Aps (DDS) c/o MC2 Biotek Group | Psoriasis vulgaris, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02038569 / 2013-001538-16: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects |
|
|
| Completed | 2 | 125 | Canada, US, Europe | LEO 80185 gel | LEO Pharma | Psoriasis Vulgaris | 02/18 | 02/18 | | |
| Completed | 2 | 30 | Europe | Betamethasone-Calcipotriene Topical | Centre Hospitalier Universitaire de Nice | Psoriasis Vulgaris | 09/18 | 03/19 | | |
2019-001189-14: A study to explore the safety and efficacy of bimiralisib applied to the skin in patients with an inflammatory skin condition |
|
|
| Not yet recruiting | 2 | 36 | Europe | Topical bimiralisib gel, Daivobet, Daivonex, PQR309, Gel, Ointment, Daivobet, Daivonex | PIQUR Therapeutics AG, PIQUR Therapeutics AG | inflammatory and hyperproliferative skin condition, inflammatory skin condition, Diseases [C] - Immune System Diseases [C20] | | | | |
